ClinicalTrials.gg
CompletedNCT04705831Updated Aug 11, 2025

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

A Phase 2 interventional study of Ruconest in Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder) and Covid19, sponsored by IMMUNOe Research Centers. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by IMMUNOe Research Centers · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Fatigue Syndrome, Chronic with a site in United States — 21 open to participants now, 24 under way, none of them phase 3. Fatigue Syndrome, Chronic · United States.

Enrollment
36th of 58
40 · median 50
Started
2021
with 7 others
Phase 2
12 of 86
4 open now
Registered
57th of 86
by date
Lead sponsor
2 of 86
IMMUNOe Research Centers

Among the 86 studies in Fatigue Syndrome, Chronic with a site in United States, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2021, is one of 12 in phase 2, and was the 57th registered.

Fatigue Syndrome, Chronic

264 studies on the registry are indexed under Fatigue Syndrome, Chronic; 62 are open to participants now.

Browse Fatigue Syndrome, Chronic studies →

Open to participants now

21 of the 86 studies in Fatigue Syndrome, Chronic with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Fatigue Syndrome, Chronic studies recruiting now, 18 (41%) set no upper age limit and 20 (45%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Fatigue Syndrome, Chronic with a site in United States, or all of them as a file.
02

Study summary

Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.

Read the detailed description

This study will last approximately 19 weeks including 16 infusions total, each one week apart. This is to help patients that have developed "Post-Viral Fatigue Syndrome" which can include symptoms such as: extreme fatigue, lost of taste, brain fog, and/or seizures.

03

Conditions studied

  • Post-Viral Fatigue Syndrome
  • Post-Viral Disorder (Disorder)
  • Covid19

Keywords

  • Post-COVID Symptoms
  • Post-Viral Fatigue Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 and older, male or female
  2. Previous confirmed diagnosis of SARS-CoV-2
  3. Experiencing SARS-CoV-2 post-viral fatigue syndrome 4 weeks after recovery for SARS-CoV-2
  4. Experiencing neurological symptoms including fatigue
  5. Willing to comply with all aspects of the protocol, including blood draws
  6. Patient is able to understand and fully participate in the activities of the study and the consent in accordance with guidelines
  7. Female patients of who are sexually active must be willing to use an acceptable form of . Acceptable forms of contraception are defined as those with a failure rate of \< 1% when properly applied and include: a combination pill, some intra-uterine devices, and a sterilized partner in a stable relationship. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period.

Exclusion criteria

Exclusion Criteria:

  1. Receiving any form of C1-INH therapy either acute or prophylactic treatment
  2. History or suspicion of allergy to rabbits
  3. Neurological conditions related to injury
  4. Neuropathy related to diabetes
  5. Participants who are pregnant or lactating
  6. Largely incapacitated or bed ridden
  7. Currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study or have discontinued with 30 days of study entry from any other clinical study involving an investigational product
  8. Patients who, in the investigator's opinion, might not be suitable for the trial for safety reasons
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    RUCONEST

    IV Ruconest

    Drug: Ruconest

  • Placebo comparator
    Placebo

    Placebo

    Drug: Ruconest

Interventions

06

What researchers measure

Primary outcomes

  1. Neuropsychological Measures (BRIEF-A)

    Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)

    Time frame: Week 0

  2. Neuropsychological Measures (BRIEF-A)

    Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)

    Time frame: Week 9

  3. Neuropsychological Measures (BRIEF-A)

    Behavior Rating Inventory of Executive Function- Adult (BRIEF-A)

    Time frame: Week 17

  4. Neuropsychological Measures (RBANS)

    Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Time frame: Week 0

  5. Neuropsychological Measures (RBANS)

    Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Time frame: Week 9

  6. Neuropsychological Measures (RBANS)

    Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    Time frame: Week 17

  7. Neuropsychological Measures (BDI II)

    Beck Depression Inventory II (BDI II)

    Time frame: Week 0

  8. Neuropsychological Measures (BDI II)

    Beck Depression Inventory II (BDI II)

    Time frame: Week 9

  9. Neuropsychological Measures (BDI II)

    Beck Depression Inventory II (BDI II)

    Time frame: Week 17

  10. Neuropsychological Measures (MoCA)

    Montreal Cognitive Assessment (MoCA)

    Time frame: Week 0

  11. Neuropsychological Measures (MoCA)

    Montreal Cognitive Assessment (MoCA)

    Time frame: Week 9

  12. Neuropsychological Measures (MoCA)

    Montreal Cognitive Assessment (MoCA)

    Time frame: Week 17

  13. Patient-Rate Questionnaires (FSS)

    Fatigue Severity Scale (FSS)

    Time frame: Week 0

  14. Patient-Rate Questionnaires (FSS)

    Fatigue Severity Scale (FSS)

    Time frame: Week 5

  15. Patient-Rate Questionnaires (FSS)

    Fatigue Severity Scale (FSS)

    Time frame: Week 9

  16. Patient-Rate Questionnaires (FSS)

    Fatigue Severity Scale (FSS)

    Time frame: Week 14

  17. Patient-Rate Questionnaires (FSS)

    Fatigue Severity Scale (FSS)

    Time frame: Week 17

  18. Patient-Rate Questionnaires (MIDAS)

    Migraine Disability Assessment (MIDAS)

    Time frame: Week 0

  19. Patient-Rate Questionnaires (MIDAS)

    Migraine Disability Assessment (MIDAS)

    Time frame: Week 5

  20. Patient-Rate Questionnaires (MIDAS)

    Migraine Disability Assessment (MIDAS)

    Time frame: Week 9

  21. Patient-Rate Questionnaires (MIDAS)

    Migraine Disability Assessment (MIDAS)

    Time frame: Week 14

  22. Patient-Rate Questionnaires (MIDAS)

    Migraine Disability Assessment (MIDAS)

    Time frame: Week 17

  23. Patient-Rate Questionnaires (HIT)

    Headache Impact Scale (HIT)

    Time frame: Week 0

  24. Patient-Rate Questionnaires (HIT)

    Headache Impact Scale (HIT)

    Time frame: Week 5

  25. Patient-Rate Questionnaires (HIT)

    Headache Impact Scale (HIT)

    Time frame: Week 9

  26. Patient-Rate Questionnaires (HIT)

    Headache Impact Scale (HIT)

    Time frame: Week 14

  27. Patient-Rate Questionnaires (HIT)

    Headache Impact Scale (HIT)

    Time frame: Week 17

  28. Patient-Rate Questionnaires (Activities)

    Activities of Daily Living Sliding Scale and Questionnaire

    Time frame: Week 0

  29. Patient-Rate Questionnaires (Activities)

    Activities of Daily Living Sliding Scale and Questionnaire

    Time frame: Week 5

  30. Patient-Rate Questionnaires (Activities)

    Activities of Daily Living Sliding Scale and Questionnaire

    Time frame: Week 9

  31. Patient-Rate Questionnaires (Activities)

    Activities of Daily Living Sliding Scale and Questionnaire

    Time frame: Week 14

  32. Patient-Rate Questionnaires (Activities)

    Activities of Daily Living Sliding Scale and Questionnaire

    Time frame: Week 17

  33. Patient-Rate Questionnaires (SF)

    SF McGill Pain Questionnaire

    Time frame: Week 0

  34. Patient-Rate Questionnaires (SF)

    SF McGill Pain Questionnaire

    Time frame: Week 5

  35. Patient-Rate Questionnaires (SF)

    SF McGill Pain Questionnaire

    Time frame: Week 9

  36. Patient-Rate Questionnaires (SF)

    SF McGill Pain Questionnaire

    Time frame: Week 14

  37. Patient-Rate Questionnaires (SF)

    SF McGill Pain Questionnaire

    Time frame: Week 17

  38. Patient-Rate Questionnaires (GSRS)

    Gastrointestinal Symptoms Rating Scale (GSRS)

    Time frame: Week 0

  39. Patient-Rate Questionnaires (GSRS)

    Gastrointestinal Symptoms Rating Scale (GSRS)

    Time frame: Week 5

  40. Patient-Rate Questionnaires (GSRS)

    Gastrointestinal Symptoms Rating Scale (GSRS)

    Time frame: Week 9

  41. Patient-Rate Questionnaires (GSRS)

    Gastrointestinal Symptoms Rating Scale (GSRS)

    Time frame: Week 14

  42. Patient-Rate Questionnaires (GSRS)

    Gastrointestinal Symptoms Rating Scale (GSRS)

    Time frame: Week 17

  43. Patient-Rate Questionnaires (SF-36)

    SF-36

    Time frame: Week 0

  44. Patient-Rate Questionnaires (SF-36)

    SF-36

    Time frame: Week 5

  45. Patient-Rate Questionnaires (SF-36)

    SF-36

    Time frame: Week 9

  46. Patient-Rate Questionnaires (SF-36)

    SF-36

    Time frame: Week 14

  47. Patient-Rate Questionnaires (SF-36)

    SF-36

    Time frame: Week 17

  48. Neurological Exam (0)

    Complete neurological examination

    Time frame: Week 0

  49. Neurological Exam (9)

    Complete neurological examination

    Time frame: Week 9

  50. Neurological Exam (17)

    Complete neurological examination

    Time frame: Week 17

  51. Immunological Biomarkers (Toll)

    Toll Like Receptor Function Assay

    Time frame: Week 1

  52. Immunological Biomarkers (Toll)

    Toll Like Receptor Function Assay

    Time frame: Week 9

  53. Immunological Biomarkers (Toll)

    Toll Like Receptor Function Assay

    Time frame: Week 17

  54. Immunological Biomarkers (GAD)

    GAD-65

    Time frame: Week 1

  55. Immunological Biomarkers (GAD)

    GAD-65

    Time frame: Week 9

  56. Immunological Biomarkers (GAD)

    GAD-65

    Time frame: Week 17

  57. Immunological Biomarkers (Com)

    Complement Panel (C4, C1-INH, C1-INH Function)

    Time frame: Week 1

  58. Immunological Biomarkers (Com)

    Complement Panel (C4, C1-INH, C1-INH Function)

    Time frame: Week 9

  59. Immunological Biomarkers (Com)

    Complement Panel (C4, C1-INH, C1-INH Function)

    Time frame: Week 17

  60. Immunological Biomarkers (Ig)

    Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)

    Time frame: Week 1

  61. Immunological Biomarkers (Ig)

    Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)

    Time frame: Week 9

  62. Immunological Biomarkers (Ig)

    Immunoglobulins-Quantitative (IgA, IgE, IgG, IgM)

    Time frame: Week 17

  63. Immunological Biomarkers (IgG)

    Immunoglobulins G, Subclasses (1-4)

    Time frame: Week 1

  64. Immunological Biomarkers (IgG)

    Immunoglobulins G, Subclasses (1-4)

    Time frame: Week 9

  65. Immunological Biomarkers (IgG)

    Immunoglobulins G, Subclasses (1-4)

    Time frame: Week 17

  66. Immunological Biomarkers (TH/TH)

    TH1/TH2 Cytokine Levels

    Time frame: Week 1

  67. Immunological Biomarkers (TH/TH)

    TH1/TH2 Cytokine Levels

    Time frame: Week 9

  68. Immunological Biomarkers (TH/TH)

    TH1/TH2 Cytokine Levels

    Time frame: Week 17

07

Study locations

1 site
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
08

References and documents

Publications

  • Melamed I, Buckley C, Bayko ME, Williams JL, Or-Geva N. Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study. Front Neurol. 2025 Nov 6;16:1523814. doi: 10.3389/fneur.2025.1523814. eCollection 2025. PubMed 41281561 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2024, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 12, 2021
StartActual
Jan 11, 2021
Primary completionActual
Mar 30, 2024
CompletionActual
Jul 1, 2024
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04705831
Lead sponsor
IMMUNOe Research Centers
Responsible party
Isaac Melamed, MD (Principal Investigator, IMMUNOe Research Centers) — Principal investigator
First posted
Jan 12, 2021
Start date
Jan 11, 2021
Primary completion
Mar 30, 2024
Completion
Jul 1, 2024
Last update
Aug 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Conestat alfa

Start the discussion